AU2013207962B2 - Immunogenic HPV L2-containing VLPs and related compositions and methods - Google Patents

Immunogenic HPV L2-containing VLPs and related compositions and methods Download PDF

Info

Publication number
AU2013207962B2
AU2013207962B2 AU2013207962A AU2013207962A AU2013207962B2 AU 2013207962 B2 AU2013207962 B2 AU 2013207962B2 AU 2013207962 A AU2013207962 A AU 2013207962A AU 2013207962 A AU2013207962 A AU 2013207962A AU 2013207962 B2 AU2013207962 B2 AU 2013207962B2
Authority
AU
Australia
Prior art keywords
hpv
vlps
virus
peptide
coat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013207962A
Other languages
English (en)
Other versions
AU2013207962A1 (en
Inventor
Bryce Chackerian
David Peabody
Ebenezer TUMBAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UNM Rainforest Innovations
Original Assignee
UNM Rainforest Innovations
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UNM Rainforest Innovations filed Critical UNM Rainforest Innovations
Publication of AU2013207962A1 publication Critical patent/AU2013207962A1/en
Application granted granted Critical
Publication of AU2013207962B2 publication Critical patent/AU2013207962B2/en
Assigned to UNM RAINFOREST INNOVATIONS reassignment UNM RAINFOREST INNOVATIONS Request to Amend Deed and Register Assignors: STC.UNM
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2795/18142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2795/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2013207962A 2012-01-12 2013-01-10 Immunogenic HPV L2-containing VLPs and related compositions and methods Ceased AU2013207962B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261585839P 2012-01-12 2012-01-12
US61/585,839 2012-01-12
PCT/US2013/020960 WO2013106525A1 (en) 2012-01-12 2013-01-10 Immunogenic hpv l2-containing vlps and related compositions and methods

Publications (2)

Publication Number Publication Date
AU2013207962A1 AU2013207962A1 (en) 2014-08-07
AU2013207962B2 true AU2013207962B2 (en) 2017-07-20

Family

ID=48781889

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013207962A Ceased AU2013207962B2 (en) 2012-01-12 2013-01-10 Immunogenic HPV L2-containing VLPs and related compositions and methods

Country Status (8)

Country Link
EP (1) EP2802349B1 (cg-RX-API-DMAC10.html)
JP (1) JP6185932B2 (cg-RX-API-DMAC10.html)
CN (1) CN104159606A (cg-RX-API-DMAC10.html)
AU (1) AU2013207962B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014017242A8 (cg-RX-API-DMAC10.html)
CA (1) CA2861021A1 (cg-RX-API-DMAC10.html)
HK (1) HK1203837A1 (cg-RX-API-DMAC10.html)
WO (1) WO2013106525A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549976B1 (en) 2012-11-16 2017-01-24 Stc.Unm Affinity selection of Nipah and Hendra virus-related vaccine candidates from a complex random peptide library displayed on bacteriophage virus-like particles
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
CA2923029A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
US9943580B2 (en) 2013-09-12 2018-04-17 Stc.Unm Malaria vaccine
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
WO2017136400A1 (en) * 2016-02-02 2017-08-10 Stc. Unm Vlp-based vaccines for targeting staphylococcus aureus secreted virulence factors
JP6916209B2 (ja) * 2016-05-13 2021-08-11 フラッシュ セラピューティクス 特に免疫応答に関与する細胞への、ｒｎａの転移のためのウイルス粒子
AU2018270111B2 (en) 2017-05-18 2022-07-14 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
CA3076631A1 (en) 2017-09-29 2019-04-04 Deutsches Krebsforschungszentrum Cutaneous papilloma virus vaccine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011100234A2 (en) * 2010-02-09 2011-08-18 Stc.Unm Immunogenic hpv l2-containing vlps and related compositions, constructs, and therapeutic methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
GB9420146D0 (en) * 1994-10-06 1994-11-23 Cancer Res Campaign Tech Papillomavirus vaccine
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US20090028886A1 (en) * 2004-08-04 2009-01-29 Cytos Biotechnology Ag Carrier conjugates of gnrh-peptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011100234A2 (en) * 2010-02-09 2011-08-18 Stc.Unm Immunogenic hpv l2-containing vlps and related compositions, constructs, and therapeutic methods

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Caldeira et al. Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7. Vaccine. 2010 Jun 17;28(27):4384-93. *
PEABODY D. S., et al, "Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2", Journal of Molecular Biology, 2008, vol 380, pages 252-263 *
TISSOT ALAIN C ET AL, "Versatile virus-like particle carrier for epitope based vaccines.", PLOS ONE 2010, vol. 5, no. 3, pages 1 - 8 *
TUMBAN EBENEZER ET AL, "A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2.", PLOS ONE, (2011), vol. 6, no. 8, pages 1 - 11 *

Also Published As

Publication number Publication date
BR112014017242A8 (pt) 2017-07-04
WO2013106525A1 (en) 2013-07-18
EP2802349A1 (en) 2014-11-19
AU2013207962A1 (en) 2014-08-07
EP2802349A4 (en) 2015-08-26
EP2802349B1 (en) 2017-12-06
HK1203837A1 (en) 2015-11-06
CN104159606A (zh) 2014-11-19
CA2861021A1 (en) 2013-07-18
JP2015504897A (ja) 2015-02-16
BR112014017242A2 (pt) 2017-06-13
JP6185932B2 (ja) 2017-08-23

Similar Documents

Publication Publication Date Title
EP2802349B1 (en) Immunogenic hpv l2-containing vlps and related compositions and methods
AU2004290032B2 (en) Optimized expression of HPV 58 L1 in yeast
RU2356943C2 (ru) Молекула нуклеиновой кислоты, кодирующая hpv31 l1, экспрессирующий вектор, клетка-хозяин, вирусоподобная частица и способ ее получения, вакцина, фармацевтическая композиция и способы с их использованием
HK1244695A1 (zh) Hpv颗粒及其用途
CA2987155A1 (en) Hpv vaccines
SG177269A1 (en) Novel human papillomavirus (hpv) protein constructs and their use in the prevention of hpv disease
JP7777890B2 (ja) Ｃｃｌ１１の用途
US20120087936A1 (en) Therapeutic and prophylactic vaccine for the treatment and prevention of papillomavirus infection
US20170096456A1 (en) Immunogenic hpv l2-containing vlps and related compositions, constructs, and therapeutic methods
US9717783B2 (en) Immunogenic HPV L2-containing VLPs and related compositions, constructs, and therapeutic methods
US8778351B2 (en) Combined human papillomavirus VLP/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
WO2016026401A1 (zh) 增强hpv抗原表位肽免疫原性的方法及类病毒颗粒、颗粒制备方法与应用
CN101115766B (zh) 用于抗人乳头瘤病毒型16的salmonella疫苗菌株的密码子经优化的hpv16l1
Zanotto et al. Construction and characterisation of a recombinant fowlpox virus that expresses the human papilloma virus L1 protein
Shokri et al. Designing of DNA vaccine based on a secretory form of major capsid protein of human papillomavirus type 18
WO2016107525A1 (zh) 一种具有抗宫颈癌细胞活性的重组疫苗构建方法及应用
Yadav Efficacy of Mixed MS2-L2 VLPs against Six HPV Types and the Development & Evaluation of Viral Structural Proteins for Assembly into VLPs
JP6916115B2 (ja) ＨＰＶＬ２ペプチド／ＨＢｓキメラタンパク質を有効成分とするＨＰＶ感染症用ワクチン
Yang Re-engineering a Nanoparticle Human Papillomavirus Prophylactic Vaccine Antigen Based on the Minor Capsid Protein L2
CN121518519A (zh) 多价猪圆环病毒疫苗
Zhai A broadly protective thermostable next generation HPV vaccine based on a concatemer peptide and a consensus peptide of L2 displayed on bacteriophage virus-like particles
Bolhassani et al. Preclinical and Clinical Experiments on HPV Vaccines
Bounds An Investigation of the Vaccine Generated Cell Mediated Immune Responses to HLA-A2. 1 Restricted HPV16E7 Epitopes in Vivo Using Two Preclinical Animal Models
Kim Current and Next-generation Vaccines against Human Papillomaviruses
Šmahel et al. ENHANCEMENT OF T CELL-MEDIATED AND HUMORAL IMMUNITY OF β-GLUCURONIDASE-BASED DNA VACCINES AGAINST HPV-16 E7 ONCOPROTEIN.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: UNM RAINFOREST INNOVATIONS

Free format text: FORMER NAME(S): STC.UNM

MK14 Patent ceased section 143(a) (annual fees not paid) or expired